Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
PHASE1CompletedINTERVENTIONAL
Enrollment
6
Participants
Timeline
Start Date
October 1, 2014
Primary Completion Date
December 25, 2014
Study Completion Date
October 17, 2017
Conditions
Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaFollicular LymphomaSmall Lymphocytic LymphomaLymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)Marginal Zone Lymphoma